#FujiPharmaceuticalIndustries

On March 11, 2026, all 16,500 units of the 2nd series stock acquisition rights of Fuji Pharmaceutical Industries Ltd. were exercised, completing fundraising of 3.3 billion yen.

The cumulative net sales for the second quarter of the fiscal year ending September 2026 have been revised upward by 1.3% from the previous forecast to JPY 29,420 million, and operating income by 47.0% to JPY 4,100 million. Conversely, net income attributable to owners of parent has been revised downward by 55.4% to JPY 860 million due to the recording...